Vanda Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was the target of some unusual options trading activity on Monday. Investors acquired 13,610 call options on the company. This represents an increase of 596% compared to the typical daily volume of 1,955 call options.

Vanda Pharmaceuticals Stock Performance

VNDA opened at $8.17 on Wednesday. The company has a market capitalization of $482.93 million, a price-to-earnings ratio of -2.19 and a beta of 0.62. The business’s 50-day moving average price is $7.38 and its two-hundred day moving average price is $5.82. Vanda Pharmaceuticals has a 1 year low of $3.81 and a 1 year high of $9.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.39 and a quick ratio of 2.38.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The firm had revenue of $57.22 million for the quarter, compared to analyst estimates of $59.28 million. Equities analysts expect that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA approval of BYSANTI expands Vanda’s psychiatry franchise, with the company planning a U.S. commercial launch in Q3 2026 and stating the drug is a new chemical entity with regulatory exclusivity and patents cited into the 2040s — a clear near‑term revenue catalyst. Vanda Pharmaceuticals surges as FDA approves BYSANTI
• Positive Sentiment: Wall Street picked up the story — recent analyst notes and buy/overweight calls (including an HC Wainwright buy on 2/23) and several raised price targets amplified optimism, supporting the rally and possibly attracting momentum traders. Analyst Expectations For Vanda Pharmaceuticals’s Future
• Neutral Sentiment: Unusual options flow: traders bought a large number of VNDA call options the day before the move (almost 6x typical daily call volume), which both amplified upside and increased volatility — this is often short‑term momentum rather than fundamental demand. (Reported market activity on 2/23.)
• Neutral Sentiment: After the big post‑approval spike, trading settled the following day as investors digested details and waited for commercial guidance and launch timing; coverage pieces explain the swift move and the subsequent calmer session. What’s going on with Vanda Pharma stock Tuesday?
• Negative Sentiment: Questions about differentiation and finances: analysis notes BYSANTI’s potential overlap with Vanda’s existing Fanapt product and flags that Vanda posted a large net loss in 2025 and expects higher cash burn in 2026 — raising funding and margin concerns that could limit long‑term upside unless sales ramp materially. Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn’t Feel Dizzy

Institutional Trading of Vanda Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Torren Management LLC bought a new position in Vanda Pharmaceuticals in the fourth quarter valued at $25,000. Russell Investments Group Ltd. lifted its position in Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 5,328 shares in the last quarter. CWM LLC boosted its stake in shares of Vanda Pharmaceuticals by 424.6% during the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 7,575 shares during the last quarter. Quarry LP bought a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $53,000. Finally, Cerity Partners LLC bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $69,000. Institutional investors own 88.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on VNDA shares. HC Wainwright upped their target price on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. B. Riley Financial raised their price objective on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, December 31st. Zacks Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Finally, Jefferies Financial Group raised their price target on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research report on Wednesday, December 31st. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $14.13.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.